Antibody-drug conjugates are generally believed to crucially rely on internalization into cancer cells for therapeutic activity. Here, we show that a non-internalizing antibody-drug conjugate, based on the F16 antibody specific to the alternatively spliced A1 domain of tenascin-C, mediates a potent therapeutic activity when equipped with the anthracycline PNU159682. The peptide linker, connecting the F16 antibody in IgG format at a specific cysteine residue to the drug, was stable in serum but could be efficiently cleaved in the subendothelial extracellular matrix by proteases released by the dying tumor cells. The results indicate that there may be a broader potential applicability of non-internalizing antibody-drug conjugates for cancer therapy than what had previously been assumed.
Introduction
The majority of small molecule anticancer therapeutics, conventionally used for cancer therapy, typically fail to localize to solid tumors [1, 2] . This pharmacokinetic limitation, which is becoming increasingly clear as a result of positron emission tomography studies with radiolabeled drugs in cancer patients [3] , may prevent dose escalation to therapeutically active regimens and cause undesired toxicity. Antibody-drug conjugates (ADCs) have been proposed as a general approach for the generation of novel cytotoxic products, with improved therapeutic index [4] [5] [6] [7] . Two ADCs have recently gained marketing authorization: Adcetris™ for the treatment of certain hematological malignancies and Kadcyla™ for the second-line treatment of HER2-positive metastatic breast cancer [8] . It is generally assumed that anticancer ADC products need to internalize into the antigen-positive tumor cells, in order to display their therapeutic action [9, 10] . Both antibodies and linker-payload combinations for ADC development have often been selected, on the basis of their potential to internalize into tumor cells after antigen binding and to be processed by intracellular agents [11, 12] . However, the strict requirement for antibody internalization has recently been questioned, as non-internalizing ADC products directed against components of the tumor extracellular matrix can efficiently liberate their drug in the extracellular space and mediate a potent therapeutic activity [13] . For example, our group has shown that non-internalizing ADCs, carrying disulfide-linked drugs at site-specific positions on the antibody molecule, can release cytotoxic drugs as a consequence of tumor cell death and sub-sequent shedding of glutathione into the surrounding milieu [14, 15] .
Until recently, studies on non-internalizing ADC products have been limited to tubulin-targeting drugs. PNU159682 has emerged as a potent anthracycline derivative, with cytotoxic activity in the picomolar concentration range [16] . This compound was identified as the most active product of metabolic conversion of Nemorubicin, carried out by the CYP3A4 enzyme [17] . Recently, PNU159682 was coupled to an internalizing anti-CD22 antibody: the resulting conjugate was administered to mice xenografted with cancer cell lines resistant to MMAE-bearing ADC analogues, exhibiting a significant antitumor effect [18] . In this study, we coupled a derivative of PNU159682 to the non-internalizing F16 antibody, specific to the alternatively-spliced A1 domain of tenascin-C [19] . This protein is one of the most abundant markers in the stroma of solid tumors [20] [21] [22] , lymphomas [23] and in the bone marrow of acute leukemias [24] , while being virtually undetectable in normal adult tissues [25, 26] . The resulting ADC product exhibited a potent anti-tumor effect in vivo.
IgG(F16) and IgG(KSF) antibodies and the ADC product F16-MMAE were prepared as previously described [28] . PNU159682 (1), MMAF and the linker-drug modules Mc-Val-Cit-PNU159682 (2) and Mc-ValCit-MMAF were purchased from Levena Biopharma. Fluorescein-5-Maleimide was purchased from Sigma-Aldrich.
Drug-mAb conjugation protocol
IgG(F16) antibody (0,9 mg/ml, 12 mg, 84 nmol) was treated with a freshly-prepared 0.1 M solution of TCEP (ACBR, 1,44 mg, 5,02 μmol, 30 eq × reactive cysteine residue) in mQ water. The mixture was reacted overnight at 4°C. The mixture was concentrated using Vivaspin™ Turbo 15 (Sartorious) and loaded on Äkta FPLC instrument (GE Healthcare), equipped with a HiPrep 26/10 Desalting column (GE Healthcare). The reduced protein was thus purified by size exclusion chromatography, using PBS as a mobile phase, with 2 ml/min flow rate. Protein-containing fractions were pooled and concentrated in order to keep the total solution volume below the capacity limit of the FPLCloop. The purification yielded 9 mg (70 nmol) of reduced protein, in 10 ml PBS. Compound 2 (2,2 mg, 14 μmol, 10 eq × reactive cysteine residue) was dissolved in DMSO (1,1 ml) and added to the reduced protein. The mixture was stirred for 1 h at RT, the reaction was then quenched with L-Cysteine (Fluka) at a final concentration of 1 mM for 10 min at RT. Final ADC F16-PNU159682 was FPLC-purified as described above, while the ADC concentration was measured following a published procedure [27] . The same procedure was followed for the preparation of ADC KSF-PNU159682. ADC products were characterized by size-exclusion chromatography, SDS-Page and Mass spectrometry, as described in the Supporting Information. The ADCs were concentrated to about 1 mg/ml. Sterile-filtered aliquots were flash-frozen in liquid nitrogen and stored at −80°C for further use. F16-MMAE and F16-MMAF ADCs were prepared and characterized following a published procedure [28] .
Linker stability in mouse serum
F16-PNU159682 was incubated at a concentration of 150 μg/ml in mouse serum (Invitrogen) at 37°C in a shaking incubator. At different time points (i.e. 48, 72, 96, 120 h), aliquots were purified by affinity chromatography onto an antigencoated resin, based on Tenascin C-A1 coupled to CNBr-activated Sepharose (GE Healthcare), washed with PBS and then eluted with 0.1 M glycine solution (pH = 3), prior to analysis by mass spectrometry. The intensity of the intact ADC signal was compared to the one of signals ascribable to PNU1596982 release from the F16 mAb (e.g. m/z 23,373.5, relative to the mAb light chain, functionalized with the hydrolyzed Val-Cit peptide). As shown in Fig.  S1 , no peaks ascribable to drug release were detected after 120 h.
Cell culture
A431 epidermoid carcinoma cells (ATCC, CRL-1555) were grown in DMEM medium (Gibco) supplemented with 10% FBS (Gibco) and Antibiotic-Antimycotic (Gibco) and incubated at 37°C in 5% CO 2 atmosphere.
Cell viability assays
Four human cancer cell lines (A431: epidermoid carcinoma, MDA- MB-231: metastatic breast cancer; U87: glioblastoma; SKRC-52: renal cell carcinoma) were incubated in 96-well plates for 72 h at 37°C and 5% CO 2 with either PNU159682 (1) or its derivative MC-Val-Cit-PNU159682 (2) at different concentrations. In a second experiment, A431 cells were seeded (5000 cells/well) and incubated for 72 h with DMEM medium (Gibco, +10% FBS) containing serial dilutions of PNU159682, MMAE and MMAF (highest concentrations tested: 5, 500 and 500 nM, respectively). The media were replaced by a solution of MTS cell viability dye (Promega) in cell medium. The plates were incubated for 3 h under culture conditions and the absorbance at 490 nm was measured on a Spectra Max Paradigm multimode plate reader (Molecular Devices). Experiments were performed in triplicate and average cell viability was calculated as measured background corrected absorbance divided by the absorbance of untreated control wells. IC 50 values were determined by fitting data to the four-parameter logistic equation, using a Prism 6 software (GraphPad Software) for data analysis.
Animal studies
Ten to twelve weeks-old female BALB/c nude mice were obtained from Janvier Laboratories (France). A431 cells (2.8 × 10 6 in 120 μl HBSS), were implanted subcutaneously in the flank. 
Therapy experiments
Sterile-filtered solutions were injected intravenously in BALB/c nude mice into the lateral tail vein, using 0.5 ml 29G insulin syringe (MicroFine™+, BD medical). Results were expressed as tumor volume in mm 3 ± SEM. In a first therapy, mice (n = 5) were injected every 3 days, 2 times in total, with F16-PNU159682 at 2 mg/kg, or with KSF-PNU159682 at 2 mg/kg, or with vehicle (PBS). In the second therapy, mice (n = 5) were injected with F16-PNU159682, KSF-PNU159682 and vehicle (PBS) every 3 days, 2 times in total at 1 mg/kg dose, whereas F16-MMAE and F16-MMAF were administered every 3 days, 4 times in total at 7 mg/kg dose. Mice were sacrificed when tumor volume reached 2000 mm 3 or when − 15% body weight loss was measured. 
Flow cytometry analysis
A431 cells cultured in a T-150 flask were detached with Accutase (ThermoFisher) and stained with Fluorescein-5-Maleimide-labelled IgG(F16), IgG(KSF) and FITC-labelled anti-CD81 (BioLegend) antibodies. All staining and washing steps were performed in 2 mM EDTA 0.5% BSA in PBS. Cells were sorted by FACS (CytoFLEX, Beckman Coulter) and analyzed using FlowJo software.
Immunohistochemistry
A431 tumors excised from mice after therapy study were embedded in OCT medium (Thermo Scientific), and cryostat sections (10 μm) were cut. Tumor sections were fixed with cold acetone before blocking with 20% FCS and 2-3% BSA in PBS. Staining of the extra-domain A1 of tenascin C was performed with the following antibodies: IgG(F16) as primary antibody; rat anti-mouse CD31 (BD Biosciences) to detect endothelial cells and rabbit anti-human Fc (Bethyl) as secondary antibodies; donkey anti-rat IgG-AlexaFluor594 (Life Technologies) and goat anti-rabbit IgG-AlexaFluor488 (Life Technologies) were then used as tertiary antibodies for microscopic detection. Nuclear staining was performed with DAPI (Thermo Scientific). Ex vivo detection of ADCs F16-PNU159682, KSF-PNU159682 and F16-MMAF was performed using the same antibodies described above, with the exclusion of the primary antibody.
Results

Cytotoxic activity of ADC payload PNU159682
The cytotoxic activity of Nemorubicin metabolite PNU159682 (1) was compared to the one of the commercial derivative Mc-Val-Cit-PNU159682 (compound 2 in Fig. 1 ), equipped with a maleimide functional group for coupling to cysteine residues, a Valine-Citrulline linker and a self-immolative spacer. The two compounds were subjected to in vitro cytotoxic assays, performed against the human cancer cell lines A431, MDA-MB-231, U87 and SKRC-52. As expected, PNU159682 displayed a potent cytotoxic activity in the subnanomolar concentration range, while compound 2 acted as a prodrug and exhibited a > 100-fold reduced activity compared to the parental compound (Fig. 1B) .
Synthesis and characterization of ADC products
The PNU159682 derivative 2 was coupled to a recombinant version of the IgG(F16) antibody, which contains a single reactive cysteine residue at the C-terminal extremity of the light chain [28] (Fig. 2) . As negative control, the KSF antibody (specific to hen egg lysozyme) was used, with an identical immunoglobulin format [28] . Fig. 2B , C shows the analytical characterization of the resulting conjugates (termed F16-PNU159682 and KSF-PNU159682) by SDS-PAGE, size-exclusion chromatography and mass spectrometry. The resulting conjugates were obtained pure, homogeneous and they displayed the expected drugantibody ratio (DAR) of 2. Incubation of F16-PNU159682 in mouse serum at 37°C showed that the Val-Cit linker is stable for over 5 days under these conditions (Fig. S1 ), in agreement with literature data [29] .
Therapy experiments
The therapeutic performance of the ADC products was tested in mice bearing A431 human epidermoid carcinoma xenografts. This cancer cell line exhibits a strong expression of A1 domain of tenascin-C around tumor blood vessels, as evidenced by immunohistochemical analysis (Fig. 3A) . Intravenous administration of the two new ADCs into tumor-bearing mice, followed by ex vivo immunofluorescence detection, revealed that F16-PNU159682 (but not KSF-PNU159682) efficiently localized around tumor blood vessels (Fig. 3C, D) .
In a first therapy experiment, we treated BALB/c nude mice with A431 tumors by administering two i.v. injections of the ADC products (2 mg/kg) or saline, starting when the neoplastic lesions had reached a size of approximately 100 mm 3 . F16-PNU159682 displayed a more potent therapeutic activity, compared to KSF-PNU159682 and to the saline control group. Complete responses were observed in animals treated with the F16 derivative, and three out of five mice were cured (Fig. 4A) . However, substantial toxicity was revealed by body weight loss. In particular, 2 mice in the F16-PNU159682 group were sacrificed at day 27 and 1 mouse in the KSF-PNU159682 at day 23. The toxicity was due, at least in part, to tumor lysis, as a reduced body weight loss was observed in the KSF treatment group. A second therapy experiment was performed, in which two injections of ADC products at 1 mg/kg dose were administered. Although these two cycles of injections did not lead to a complete tumor eradication, mice treated with F16-PNU159682 experienced a significant stabilization (> 30 days) of the tumor volume (Fig. 4B) . Also in this case, control ADC product KSF-PNU159682 was found to retard tumor growth, even though the tumor volumes progressively increased over the experiment. Importantly, under these experimental conditions, no acute toxicity and no significant body weight loss was observed for the groups of mice treated with the ADC products, as highlighted in Fig. 4B. 
Analysis of cell-killing mechanism
A microscopic hematoxylin/eosin (H & E) analysis of tumor sections, obtained three days after the second ADC injection, revealed the onset of a substantial cell death in the F16-PNU159682 treatment group, as compared to saline treatment (Fig. 5) . This necrosis was localized mainly in the inner part of the tumor mass, whereas vital areas were localized in the peripheral tumor regions (i.e., where nutrients are more easily provided from blood stream).
To verify that the F16-PNU159682 is generally not processed by tumor cells through receptor-mediated endocytosis, we performed flow cytometry experiments using both F16 and KSF antibodies, site-specifically labelled with Fluorescein-5-Maleimide at the engineered Cys residues. As reported in Fig. 6A , the two antibodies similarly showed no binding to A431 cells, whereas the latter were strongly positive for a third fluorescent mAb, specific to the transmembrane protein CD81 [30] .
The ability of F16-based ADCs to mediate anticancer activity in vivo through an extracellular payload release mechanism was also investigated by functionalizing the mAb with two closely-related dolastatin analogues (MMAE and MMAF), which strongly differ in terms of their ability to enter tumor cells. As illustrated in Fig. 6B , MMAF is a hydrophilic derivative of monomethyl auristatin E (MMAE), in which the ephedrine moiety is substituted with a C-terminal phenylalanine residue. While MMAE and MMAF are similarly potent when released intracellularly by internalizing ADC products [31] , the two drugs display very different cytotoxicity properties when added to the supernatant of tumor cell cultures. Indeed, MMAE kills various types of tumor cells in the subnanomolar concentration range, while its charged MMAF counterpart typically fails to induce cell death at concentrations below 100 nM [31] . Within the ADC context, recent findings further indicate that the lipophilic MMAE payload diffuses more efficiently towards antigen-negative cells than the MMAF [32] . Firstly, we incubated the A431 cancer cells with decreasing concentrations of free MMAE and MMAF payloads. In keeping with literature data, MMAE and MMAF showed IC 50 values of 0.3 and 134 nM, respectively (Fig. 6C) . Subsequently, the two auristatins were coupled to the F16 antibody through a cleavable Val-Cit linker and injected four times into A431-bearing mice, at the dose of 7 mg/kg. The in vivo anticancer properties of the two ADCs were in line with the cytotoxic activities observed in vitro with the free payloads. While F16-MMAE induced a rapid tumor regression, the F16-MMAF conjugate did not display any detectable therapeutic activity (Fig. 6D) , in spite of its ability to efficiently localize to the tumor site, as indicated by ex vivo immunofluorescence analysis (Fig. 6E ).
Discussion
A direct internalization into the target tumor cells has often been presented as an important requirement for ADC activity. From a theoretical point of view, internalizing ADCs should be ideally suited for the delivery of cytotoxic agents into the neoplastic cells. However, most ADC products described so far rely on the use of linkers (e.g., the Val-Cit dipeptide) which are not sufficiently stable in circulation or in the tumor microenvironment. For instance, Dorywalska and co-workers have recently described carboxylesterase 1C as a potential source of proteolytic activity for the cleavage of Val-Cit linkers in the tumor extracellular milieu [33] .
Interestingly, recent clinical data have shown that several large Bcell lymphoma patients expressing little-to-no CD30 antigen enjoyed complete tumor remission after monotherapy with Adcetris™ [34] . Tumor-infiltrating immune cells (e.g. macrophages) [35] may also contribute to the extracellular activation of ADC products at the tumor site.
While the ADC internalization process can be effectively monitored in vitro, it is extremely difficult to quantify in vivo (e.g., in patients) the amount of payload that is released inside the cancer cells, rather than in the extracellular environment. Our group has reported a potent anti- cancer activity for non-internalizing ADC products, which are specific to components of the modified extracellular matrix of many tumor types. Such products exhibit an efficient and selective uptake at the tumor site, as demonstrated by dosimetry studies both in mice and humans [36, 37] .
The experimental data presented herein, indicate that non-internalizing ADC products can be potently active in preclinical models of cancer. Our findings complement previous reports on the anti-cancer activity of non-internalizing ADC products, directed against collagen IV [38] and fibrin [39] . It is conceivable that the Val-Cit linker, connecting the F16 antibody to PNU159682, is cleaved by proteases that are mainly intracellular (e.g., cathepsin B), but that are released in the extracellular space upon tumor cell death. The acidic tumor microenvironment may facilitate the activation of these hydrolytic enzymes, triggering drug release by proteolysis [40] .
We have recently shown that other peptide linkers, such as the ValAla peptide sequence, can be as effective as Val-Cit in releasing cytotoxic payloads in the extracellular tumor environment [41] . Moreover, the data presented in this article indicate that lipophilic drugs may be the preferred type of cytotoxic payloads, as hydrophilic or charged drugs released in the extracellular environment fail to subsequently cross the tumor cell membrane. Thanks to the high potency of the anthracycline used in this study, two injections of the F16-PNU159682 conjugate (DAR = 2) at 1 mg/kg dose were sufficient to stop tumor growth for > 20 days in all treated mice. At higher doses, tumors could be eradicated, but a substantial loss of body weight was observed. When tubulin-interacting drugs (i.e., DM1 and MMAE) [14, 28] were used as payloads for non-internalizing antibodies, more than three cycles of injections at > 5 mg/kg were required in order to achieve cancer cures in the same animal models. It is conceivable that tubulin poisons may preferentially kill rapidly-dividing cells, while anthracyclines may also act against quiescent cells, both in the tumor and in normal organs, thus potentially contributing to undesired toxicity [42] .
Conclusions
Various ADC products have shown encouraging anticancer activity in preclinical cancer models, but this novel class of therapeutic agents typically fails to induce complete responses in patients with metastatic solid tumors. Alternatively-spliced isoforms of extracellular matrix proteins (e.g., fibronectin and tenascin-C isoforms) are abundant and easily accessible in perivascular areas of most solid malignancies, lymphomas and leukemias. These antigens represent promising targets for antibody-based drug delivery applications, as a selective and longlasting antibody accumulation at the neoplastic site has been observed both in quantitative biodistribution studies in tumor-bearing mice and in imaging studies in patients with cancer [36, 37, 43] . Payloads released in the extracellular environment may diffuse within the tumor mass, thus leading to a pharmacodynamics effect which is different from the one of internalizing ADC products. Both protease-sensitive linkers and disulfides can be conceived for drug release in the tumor extracellular space. However, it is difficult to predict clinical activity on the basis of preclinical findings, as the concentrations of extracellular proteases could be different in the two species. The findings of this study may be relevant not only for the development of non-internalizing ADC products, but also for other classes of targeted cytotoxics. For example, we and others have recently observed that small ligands directed against non-internalizing antigens (such as carbonic anhydrase IX) may be able to selectively accumulate at the tumor site [44, 45] and could therefore be used as antibody substitutes. Also in case of noninternalizing small molecule-drug conjugates, a potent and selective anticancer activity was observed using both disulfide [46] and peptide linkers [47, 48] .
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